Major Investor Avoro Acquires $25M in Warrants at Discount in Whitehawk Therapeutics' PIPE Financing

summarizeSummary

Avoro Capital Advisors and affiliates, including director Behzad Aghazadeh, acquired $25 million in pre-funded warrants as part of Whitehawk Therapeutics' recently announced $87.5 million private placement, increasing their beneficial ownership to 19.99%.

check_boxKey Events

• Major Investor Participation

  Avoro Capital Advisors and affiliates, including director Behzad Aghazadeh, acquired $25 million in pre-funded warrants as part of the company's $87.5 million private placement announced on May 13, 2026.

• Warrant Terms and Pricing

  The pre-funded warrants were purchased at $3.9199 per share, with an exercise price of $0.0001, representing a discount to the current market price of $5.20 per share.

• Increased Beneficial Ownership

  The reporting persons now beneficially own 19.99% of Whitehawk Therapeutics' common stock, subject to a 19.99% beneficial ownership blocker on warrant exercise.

auto_awesomeAnalysis

This Schedule 13D/A details the participation of major investor Avoro Capital Advisors and its affiliates, including director Behzad Aghazadeh, in Whitehawk Therapeutics' recently announced $87.5 million private placement. Avoro acquired $25 million worth of pre-funded warrants at a purchase price of $3.9199 per share, a discount to the current market price. While the financing provides crucial capital for the company's strategic shift and ADC pipeline development, the dilutive pricing of the warrants could put pressure on existing shareholders. The 19.99% beneficial ownership blocker limits immediate dilution from warrant exercise but also caps the investor's immediate voting power.